The estimated Net Worth of Nicole Seligman is at least $744 Mille dollars as of 19 November 2019. Ms. Seligman owns over 5,000 units of MeiraGTx plc stock worth over $20,800 and over the last 6 years she sold MGTX stock worth over $0. In addition, she makes $723,405 as Independent Director at MeiraGTx plc.
Sign up
Ms. Seligman MGTX stock SEC Form 4 insiders trading
Nicole has made over 1 trades of the MeiraGTx plc stock since 2019, according to the Form 4 filled with the SEC. Most recently she bought 5,000 units of MGTX stock worth $81,550 on 19 November 2019.
The largest trade she's ever made was buying 5,000 units of MeiraGTx plc stock on 19 November 2019 worth over $81,550. On average, Nicole trades about 625 units every 0 days since 2019. As of 19 November 2019 she still owns at least 5,000 units of MeiraGTx plc stock.
You can see the complete history of Ms. Seligman stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Nicole Seligman biography
Nicole K. Seligman J.D. serves as Independent Director of the Company. Ms. Seligman was the President of Sony Entertainment, Inc. from 2014 to 2016 and of Sony Corporation of America from 2012 to 2016. In those roles, she helped to drive profitability, growth, and innovation in Sony’s entertainment sector; oversaw key HQ functions for Sony’s entertainment subsidiaries; and oversaw all corporate functions of the company’s U.S. headquarters. From 2005 through 2014, she served as the global General Counsel of Sony Corporation. In that period, she had general oversight of Sony’s worldwide legal and compliance matters and, at various times, was also responsible for trade, internal audit, SOX, group risk and other corporate functions globally. She joined Sony in 2001 as Executive Vice President and General Counsel of Sony Corporation of America. Prior to joining Sony, she was a partner in the litigation practice at Williams & Connolly LLP where she worked on a broad range of complex civil and criminal matters and counseled a broad range of clients, including President William Jefferson Clinton and Hillary Clinton. Ms. Seligman received her B.A., magna cum laude, from Harvard College (Radcliffe) and her J.D., magna cum laude, from Harvard Law School, where she was a winner of the Sears Prize.
What is the salary of Nicole Seligman?
As the Independent Director of MeiraGTx plc, the total compensation of Nicole Seligman at MeiraGTx plc is $723,405. There are 7 executives at MeiraGTx plc getting paid more, with Alexandria Forbes having the highest compensation of $8,480,260.
How old is Nicole Seligman?
Nicole Seligman is 62, she's been the Independent Director of MeiraGTx plc since 2019. There are 5 older and 11 younger executives at MeiraGTx plc. The oldest executive at MeiraGTx Holdings plc is Arnold Levine, 80, who is the Independent Director.
What's Nicole Seligman's mailing address?
Nicole's mailing address filed with the SEC is 450 EAST 29TH STREET, 14TH FLOOR, NEW YORK, NY, 10016.
Insiders trading at MeiraGTx plc
Over the last 6 years, insiders at MeiraGTx plc have traded over $7,031,523 worth of MeiraGTx plc stock and bought 9,222,038 units worth $85,317,799 . The most active insiders traders include Advisors Llcperceptive Life..., Joel S Marcus e Life Sciences Master Fund L.... On average, MeiraGTx plc executives and independent directors trade stock every 33 days with the average trade being worth of $672,044. The most recent stock trade was executed by Advisors Llcperceptive Life... on 12 August 2024, trading 1,250,000 units of MGTX stock currently worth $5,000,000.
What does MeiraGTx plc do?
meiragtx, a london and new york-based gene therapy company, is committed to the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. we are pioneering the use of gene therapy to treat devastating neurodegenerative diseases such as alzheimer’s disease (ad), parkinson’s disease (pd), and amyotrophic lateral sclerosis (als). we are developing innovative gene therapies for ocular diseases including rare inherited blindness and age-related macular degeneration (amd). meiragtx is also establishing treatments for xerostomia, a frequent and debilitating side effect of radiation treatment used in head and neck cancers. our revolutionary gene regulation technologies promise to transform the way gene therapy can be applied and create new paradigms for biologic therapeutics.
What does MeiraGTx plc's logo look like?
Complete history of Ms. Seligman stock trades at MeiraGTx plc e Far Peak Acquisition Corp
MeiraGTx plc executives and stock owners
MeiraGTx plc executives and other stock owners filed with the SEC include:
-
Alexandria Forbes,
President, Chief Executive Officer, Director -
Richard Giroux,
Chief Financial Officer, Chief Operating Officer -
Dr. Alexandria Forbes,
CEO, Pres & Director -
Martin Indyk,
Independent Director -
Richard Brian Giroux B.A.,
COO & CFO -
Stuart Naylor,
Chief Development Officer -
Dr. Stuart Naylor Ph.D.,
Chief Devel. Officer -
Nicole Seligman,
Independent Director -
Keith Harris,
Independent Chairman of the Board -
Neil Mendoza,
Independent Director -
Joel Marcus,
Independent Director -
Arnold Levine,
Independent Director -
Thomas Shenk,
Independent Director -
Ellen Hukkelhoven,
Independent Director -
Elizabeth Broder,
Investor Relations -
Dr. Robert K. Zeldin M.D.,
Chief Medical Officer -
Dr. Alastair Leighton,
Sr. VP of Manufacturing & Supply Chain -
Tim Randall,
Sr. VP of Risk & Internal Controls -
Joel P. Brooks,
Sr. VP of Fin. -
Christine Elise Sheehy,
Sr. VP of Global Integration -
Dr. Michel Michaelides M.D.,
Head of Clinical Ophthalmology -
Robert J. Wollin J.D.,
Gen. Counsel & Sec. -
& Johnson Innovation Jjdc...,
10% owner -
Advisors Llcperceptive Life...,
-
Katherine Breedis,
Chief Financial Officer -
Life Sciences Master Fund L...,
-
Bruce Gottlieb,
General Counsel -
Advisors Llcedelman Joseph ...,
-
Debra Yu,
-
Robert K Zeldin,
CHIEF MEDICAL OFFICER -
Robert J Wollin,
GENERAL COUNSEL AND SECRETARY